Trial Profile
A Single-arm, Multi-Center, Open-Label Study to Evaluate the Efficacy, Safety and Pharmacokinetics of Melphalan/HDS Treatment in Patients With Hepatic-Dominant Ocular Melanoma
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 11 Mar 2024
Price :
$35
*
At a glance
- Drugs Melphalan (Primary)
- Indications Liver metastases
- Focus Registrational; Therapeutic Use
- Acronyms FOCUS
- Sponsors Delcath Systems
- 08 Mar 2024 This trial has been discontinued in Italy, according to European Clinical Trials Database record.
- 16 Jan 2024 According to a Delcath Systems media release, Dr. Jonathan S. Zager, M.D., was the global Lead Investigator for the FOCUS Phase 3 trial. Dr. Zager enrolled and treated the first and last patients in this trial and the team at Moffitt has performed the procedure over 200 times to date.
- 20 Dec 2023 Status changed from active, no longer recruiting to completed.